Physician profile
Alberto Martinez
NPI 1174768816
$4,964.52
in general payments reported to CMS, 2019-2025
35 companies · $792 in 2025
The $792 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $82.91 · 2021: $328 · 2022: $706 · 2023: $1,474 · 2024: $1,163 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,418 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,417.50 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,230.58 | 2019-2025 | |
| Amgen INC. | $627.24 | 2019-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $457.64 | 2019-2025 | |
| Lilly USA, LLC | $444.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $375.63 | 2022-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $273.64 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $238.98 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $206.36 | 2019-2025 | Airsupra, Farxiga |
| Smith+Nephew, INC. | $128.92 | 2022-2025 | Collagenase Santyl |
| Dexcom, INC. | $86.69 | 2021-2025 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $80.32 | 2021-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $79.65 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.91 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $62.73 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $60.50 | 2023 | Quviviq |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $46.67 | 2019 | |
| Allergan, INC. | $45.79 | 2019-2020 | |
| Boston Scientific Corporation | $45.36 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $38.10 | 2021 | |
| Viiv Healthcare Company | $36.98 | 2023-2024 | Apretude |
| Takeda Pharmaceuticals U.S.A., INC. | $29.81 | 2022 | |
| Mimedx Group, INC. | $26.78 | 2025 | |
| Exact Sciences Corporation | $26.64 | 2025 | The Cologuard Plus Collection Kit |
| Sanofi Pasteur INC. | $26.45 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $25.72 | 2025 | Vaxneuvance, Vaxelis, Rotateq |
| Paratek Pharmaceuticals, INC. | $25.36 | 2025 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $22.48 | 2025 | Eliquis |
| Amarin Pharma, INC. | $21.57 | 2019 | |
| Koya Medical, INC. | $20.55 | 2025 | Dayspring, Koya Medical |
| Biohaven Pharmaceutical Holding Company LTD. | $19.74 | 2022 | |
| Astellas Pharma US INC | $19.34 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.31 | 2019 | |
| Medtronic, INC. | $16.11 | 2024 | Venaseal |
| Sunovion Pharmaceuticals INC. | $14.90 | 2020 | |
| Horizon Therapeutics Plc | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.